Article

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Annals of the rheumatic diseases (Impact Factor: 10.38). 02/2011; 70(5):823-6. DOI: 10.1136/ard.2010.140822
Source: PubMed

ABSTRACT The British Society for Rheumatology Biologics Register (BSRBR) has collected data on adverse events including pregnancies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor (anti-TNF) therapy. The purpose of this report is to summarise the pregnancy outcomes in women treated with anti-TNF in the BSRBR.
Patients were categorised according to anti-TNF exposure as follows: (1) exposure to anti-TNF and to methotrexate (MTX) and/or leflunomide (LEF) at conception (n=21 pregnancies); (2) exposure to anti-TNF at conception (n=50); (3) exposure to anti-TNF prior to conception (n=59); (4) no exposure to anti-TNF (control group; n=10).
Eighty-eight live births in a total of 130 pregnancies were reported in patients who received anti-TNF before or during pregnancy. The rate of spontaneous abortion was highest among patients exposed to anti-TNF at the time of conception (with MTX/LEF 33% and without MTX/LEF 24%). This compared with 17% spontaneous abortions in those with prior exposure to anti-TNF and 10% spontaneous abortions in the control group. Ten terminations were performed.
Although the results to date have been promising, no firm conclusions can be drawn about the safety of anti-TNF during pregnancy and, without further evidence, guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed.

Download full-text

Full-text

Available from: Suzanne M M Verstappen, Sep 02, 2015
0 Followers
 · 
90 Views
 · 
31 Downloads
  • Source
    • "There is at least one report of genital bleeding at 7 days post-partum in a patient in whom certolizumab had been discontinued 9 weeks earlier [179]. A recent report from the BSRBR discussed the occurrence of adverse events of anti-TNF therapy during pregnancy [180]. They analyzed collected data from the BSRBR of 130 pregnancies and concluded that at the time of conception treatment with anti-TNF therapy may increase the risk of spontaneous abortion. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated with an increased risk of RA. Traditionally RA has been treated with disease modifying anti-rheumatic drugs (DMARDs) but in the last 15 years or so the introduction of biological response modifiers has revolutionized the treatment of RA. Among these anti-tumor necrosis factor (TNF) agents were the first to be successfully used in treating RA. The goal in treating RA is to induce remission or very low disease activity; remission is now accepted as the ultimate therapeutic goal by adoption of a "treat to target" strategy to achieve tight disease control. Therefore early diagnosis, as well as immediate intervention, are of the utmost importance. This review of the role of TNF in RA pathogenesis describes the mechanisms of action of currently used anti-TNF agents and the adverse events and safety of these drugs. Guidance on the use of anti-TNFs during pregnancy and prior to surgical procedures is also discussed. The intense efforts currently being made to identify biomarkers of response to anti-TNF therapy and recent progress in defining genetic predictors of response using genome- wide association studies (GWAS) are covered. However, so far, none of these studies have been translated into clinical application. The development of biosimilars or follow-on biologicals is also discussed and the first reported study of a biosimilar, involving a multicenter study of an etanercept biosimilar, Etanar, is described.
    Current pharmaceutical design 08/2011; 17(29):3141-54. DOI:10.2174/138161211798157658 · 3.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Augenerkrankungen müssen auch während der Schwangerschaft und Stillzeit behandelt werden. Der Einsatz von Medikamenten birgt ein Risiko für Mutter und Kind. Der Beitrag gibt den Kenntnisstand zur Anwendung der wichtigsten Ophthalmika in der Schwangerschaft und Stillzeit wieder. Erörtert werden die Diagnostik am Auge (Tonometrie, Mydriasis, Angiographie) und die Behandlung von Infektionen am Auge, Glaukom, Allergien, diabetische Retinopathie, Schmerzen oder Entzündungen.
    Der Ophthalmologe 03/2012; 109(3). DOI:10.1007/s00347-011-2459-x · 0.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treating psoriasis in pregnant and lactating women presents a special challenge. For ethical reasons, prospective randomized control trials have not been conducted in this patient population although these patients do encounter new-onset psoriasis in addition to flares and may require treatment throughout their pregnancies. Our aim was to arrive at consensus recommendations on treatment options for psoriasis in pregnant and lactating women. The literature was reviewed regarding all psoriasis therapies in pregnant and lactating women. Topical therapies including emollients and low- to moderate-potency topical steroids are first-line therapy for patients with limited psoriasis who are pregnant or breast-feeding. The consensus was that second-line treatment for pregnant women is narrowband ultraviolet B phototherapy or broadband ultraviolet B, if narrowband ultraviolet B is not available. Lastly, tumor necrosis factor-α inhibitors including adalimumab, etanercept, and infliximab may be used with caution as may cyclosporine and systemic steroids (in second and third trimesters). Some specific strategies may be used to minimize risk and exposure. There are few evidence-based studies on treating psoriasis in pregnant and lactating women. Because there will always be a question of ethical concerns placing pregnant and lactating women in prospective clinical trials, investigation of both conventional and biologic agents are unlikely to ever be performed. Some of these medications used to treat psoriasis are known abortifacients, mutagens, or teratogens and must be clearly avoided but others can be used with relative confidence in select patients with appropriate counseling of risks and benefits.
    Journal of the American Academy of Dermatology 10/2011; 67(3):459-77. DOI:10.1016/j.jaad.2011.07.039 · 5.00 Impact Factor
Show more